Jan 8, 2020 ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
Dec 10, 2019 ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Nov 7, 2019 ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
Nov 7, 2019 ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease